- Regulatory feedback and alignment from both U.S. and ex- U.S. regulators supports clinical development path for PBGENE-HBV - IND/CTA enabling studies with final clinical candidate underway for PBGENE-HBV program; expect to file IND and/or CTA in 2024 - Expected to be the first and only